Drug-Induced liver injury with hypersensitivity features has a better outcome: A single-center experience of 39 children and adolescents

Hepatology

Volumn 54, Issue 4, 2011, Pages 1344-1350

  Devarbhavi, Harshad ^a   Karanth, Dheeraj ^a   Prasanna, K S ^a   Adarsh, C K ^a   Patil, Mallikarjun ^a  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AYURVEDIC DRUG; CARBAMAZEPINE; CIPROFLOXACIN; COTRIMOXAZOLE; DAPSONE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; ETHAMBUTOL; FERROUS SULFATE; ISONIAZID; MERCAPTOPURINE; METHOTREXATE; NIMESULIDE; OXYCARBAMAZEPINE; PHENYTOIN; PYRAZINAMIDE; RIFAMPICIN; UNCLASSIFIED DRUG;

ACUTE LIVER FAILURE; ADOLESCENT; ADULT; ARTICLE; ASCITES; BRAIN DISEASE; CHILD; CHILDHOOD MORTALITY; CLINICAL ARTICLE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEMALE; FEVER; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LYMPHADENOPATHY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; ROUSSEL UCLAF CAUSALITY ASSESSMENT METHOD; SCHOOL CHILD; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SURVIVAL; TOXIC HEPATITIS;

ADOLESCENT; AGE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG HYPERSENSITIVITY; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; INCIDENCE; INDIA; MALE; PHARMACEUTICAL PREPARATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 80053314253     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24527     Document Type: Article

References (44)

1. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al.; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521.
2. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. HEPATOLOGY 2005; 42: 481-489.
3. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al.; Drug-Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934.
4. Devarbhavi H, Dierkhsing R, Kremers W, Sandeep MS, Karanth D, Adarsh CK. Single center experience with drug induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105: 2396-2404.
5. Wai CT, Tan BH, Chan CL, Sutedja DS, Lee YM, Khor C, et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 2007; 27: 465-474.
6. Squires RH, Jr., Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, Dhawan A. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148: 652-658.
7. Piñeiro-Carrero VM, Piñeiro EO. Liver. Pediatrics 2004; 113(Suppl): 1097-1106.
8. Buratti S, Lavine JE. Drugs and the liver: advances in metabolism, toxicity, and therapeutics. Curr Opin Pediatr 2002; 14: 601-607.
9. Berkowitz FE, Henderson SL, Fajman N, Schoen B, Naughton M. Acute liver failure caused by isoniazid in a child receiving carbamazepine. Int J Tuberc Lung Dis 1998; 2: 603-606.
10. Gökçe S, Durmaz O, Celtik C, Aydogan A, Güllüoglu M, Sökücü S. Valproic acid-associated vanishing bile duct syndrome. J Child Neurol 2010; 25: 909-911.
11. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al.; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954.
12. Murray KF, Hadzic N, Wirth S, Bassett M, Kelly D. Drug-related hepatotoxicity and acute liver failure. J Pediatr Gastroenterol Nutr 2008; 47: 395-405.
13. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009; 15: 719-729.
14. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009; 29: 337-347.
15. Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol 2010; 70: 721-728.
16. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
17. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-276.
18. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 1999.
19. Chalasani N. Pediatric DILI in the United States. FDA-AASLD-PHARMA DILI conference. 2010 Hepatotoxicity-Session I. Available online at http://www.aasld.org/conferences/Documents/Presentation Library/2010Hepatoxicity-SessionI-Chalasani.pdf. Accessed December 18, 2010.
20. Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. HEPATOLOGY 2009; 49: 2001-2009.
21. Kumar R, Shalimar, Bhatia V, Sreenivas V, Gupto SD, Panda SK, et al. Antitubercular therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. HEPATOLOGY 2010; 51: 1665-1674.
22. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471.
23. Roy B, Ghosh SK, Sutradhar D, Sikdar N, Mazumder S, Barman S. Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J Gastroenterol Hepatol 2006; 21: 784-786.
24. Devrim I, Olukman O, Can D, Dizdarer C. Risk factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults. Chest 2010; 137: 737-738.
25. Wu SS, Chao CS, Vargas JH, Sharp HL, Martín MG, McDiarmid SV, et al. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation 2007; 84: 173-179.
26. Devarbhavi H, Ross D, Kremers W. Antituberculosis therapy drug-induced liver injury and acute liver failure. HEPATOLOGY 2010; 52: 798-799.
27. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. HEPATOLOGY 2010; 52: 2065-2076.
28. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. HEPATOLOGY 2010; 51: 615-620.
29. Rakhmanina NY, Capparelli EV, van den Anker JN. Personalized therapeutics: HIV treatment in adolescents. Clin Pharmacol Ther 2008; 84: 734-740.
30. Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf 2002; 25: 111-133.
31. Wright JM, Stokes EF, Sweeney VP. Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction. N Engl J Med 1982; 307: 1325-1327.
32. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008; 118: 281-290.
33. Björnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007; 25: 1411-1421.
34. Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol 2006; 44: 791-797.
35. Carroll MC, Yueng-Yue KA, Esterly NB, Drolet BA. Drug-induced hypersensitivity syndrome in pediatric patients. Pediatrics 2001; 108: 485-493.
36. Hayashi PH, Watkins P. Progress in our understanding of severe drug-induced liver injury. Liver Transpl 2009; 15: 675-676.
37. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155: 2285-2290.
38. Bessmertny O, Hatton RC, Gonzalez-Peralta RP. Antiepileptic hypersensitivity syndrome in children. Ann Pharmacother 2001; 35: 533-538.
39. Andrade RJ, Robles M, Lucena MI. Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin Drug Saf 2009; 8: 709-714.
40. Hunt CM. Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. HEPATOLOGY 2010; 52: 2216-2222.
41. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 82: 128-134.
42. Adam de Beaumais T, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K, et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol 2011; 71: 575-584.
43. Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. HEPATOLOGY 2010; 52: 730-742.
44. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al.; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf Causality Assessment Method. HEPATOLOGY 2010; 51: 2117-2126.